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Patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) have high
risk of microcirculation complications and microangiopathies. An increase in thrombogenic
risk is associated with platelet hyperaggregation, hypercoagulation, and hyperfibrinolysis.
Factors leading to platelet activation in MetS and T2DM comprise insulin resistance,
hyperglycemia, non-enzymatic glycosylation, oxidative stress, and inflammation. This
review discusses the role of nitric oxide (NO) in the regulation of platelet adhesion
and aggregation processes. NO is synthesized both in endotheliocytes, smooth muscle
cells, macrophages, and platelets. Modification of platelet NO-synthase (NOS) activity
in MetS patients can play a central role in the manifestation of platelet hyperactivation.
Metabolic changes, accompanying T2DM, can lead to an abnormal NOS expression
and activity in platelets. Hyperhomocysteinemia, often accompanying T2DM, is a risk
factor for cardiovascular accidents. Homocysteine can reduce NO production by platelets.
This review provides data on the insulin effects in platelets. Decrease in a number
and sensitivity of the insulin receptors on platelets in T2DM can cause platelet
hyperactivation. Various intracellular mechanisms of anti-aggregating insulin effects are
discussed. Anti-aggregating effects of insulin are mediated by a NO-induced elevation
of cGMP and upregulation of cAMP- and cGMP-dependent pathways. The review
presents data suggesting an ability of platelets to synthesize humoral factors stimulating
thrombogenesis and inflammation. Proinflammatory cytokines are considered as markers
of T2DM and cardiovascular complications and are involved in the development of
dyslipidemia and insulin resistance. The article provides an evaluation of NO-mediated
signaling pathway in the effects of cytokines on platelet aggregation. The effects of the
proinflammatory cytokines on functional activity of platelets are demonstrated.
Keywords: platelets, metabolic syndrome, type 2 diabetes mellitus, nitric oxide, nitric oxide synthase, cyclic
guanosine monophosphate
Metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM)
are the factors of cardiovascular risk. MetS comprises an array of
pathogenetically interrelated metabolic and clinical abnormali-
ties (insulin resistance, arterial hypertension, and dyslipidemia)
and increases risk of atherosclerotic damage of blood vessels.
Abbreviations: 5′AMP, adenosine 5′ monophosphate; 5′GMP, guanosine 5′-
monophosphate; AC, adenylate cyclase; ADP, adenosine diphosphate; ATP,
adenosine triphosphate; Ca2+-ATPase, calcium ATPase; cAMP, cyclic adeno-
sine monophosphate; cGMP, cyclic guanosine monophosphate; COX, cyclooxy-
genase; DAG, diacylglycerol; ER, endoplasmic reticulum; GC, guanylate cyclase;
GP Iib/IIIa, glycoprotein IIb/IIIa (also known as integrin αIIbβ3); GTP, guano-
sine triphosphate; ITP-3, inositol trisphosphate; NO, nitric oxide; NOS, nitric oxide
synthase; PDE4, phosphodiesterase 4; PDE5, phosphodiesterase 5; PF, platelet fac-
tor; PGG2, prostaglandin G2; PGH2, prostaglandin H2; PKA, protein kinase A;
PKG, protein kinase G; PLA2, phospholipase A2; PLC, phospholipase C; TXA2,
thromboxane A2; vWF, von Willebrand factor.
An increase in thrombogenic risk in patients with MetS and
T2DM is considered to be caused by platelet hyperaggrega-
tion and hypercoagulation due to elevated level of fibrinogen,
increased activity of blood-coagulation factors, and hyperfibri-
nolysis (Medvedev et al., 2004; Matsakaria et al., 2006; Idrisova
et al., 2007). Metabolic abnormalities, associated with insulin
resistance syndrome, significantly affect functional activity of
platelets (Schaeffer et al., 1999; Suslova et al., 2007). Activation of
platelets can play an important role in progression of heart fail-
ure due to a formation of the microthrombi in the myocardial
microcirculation (Serebruany et al., 2002).
According to the results presented by G. G. Petrik and S. A.
Pavlishchuk, the augmentation of platelet aggregation activity in
T2DM is caused by the altered metabolism: phase I of platelet
aggregation is associated with the changes in blood plasma
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protein and lipid contents; phase II is associated with an increased
number of polymorphonuclear granulocytes and dyslipidemia
(Petrik and Pavlishchuk, 2008). The study also demonstrated
an increase in the mean platelet diameter in T2DM patients
(Pavlishchuk et al., 2007). According to other study, the platelet
size and cell volume do not differ between T2DM patients and
healthy volunteers (Schaeffer et al., 1999).
Several publications provide evidence of putative interrela-
tions between the MetS components and blood platelet count.
Kotani K. et al. showed that blood platelet number in the individ-
uals presented with three and more MetS components is signifi-
cantly higher than in the presence of only one or two components
or without MetS components at all (Kotani et al., 2007). Strong
positive correlation between blood platelet count and the number
of present MetS components was documented upon adjustment
for a variety of biosocial factors (age, smoking, alcohol use, and
physical activity). Therefore, thrombocytosis can partially explain
the augmented cardiovascular risk in MetS patients (Muratova,
2004; Berkovskaya and Butrova, 2009).
There is evidence (Idrisova et al., 2007) that spontaneous
platelet aggregation, estimated based on the sizes of the formed
aggregates, was significantly higher in MetS patients compared
with healthy volunteers. The curves of the mean aggregate sizes
and light transmission characteristics suggested that the rates
of collagen-induced aggregation of isolated platelets in MetS
patients significantly exceeded the corresponding values in group
of healthy volunteers (Idrisova et al., 2007). Several publications
suggest that platelet sensitivity in T2DM patients increases due
to action of the various platelet aggregation inductors including
ADP, thrombin, and collagen (Kutti et al., 1986; Bode-Böger et al.,
1998; Tokuda et al., 2012). Correlation analysis reveals the pres-
ence of direct relationship between the glycated hemoglobin levels
and the rates of collagen- and ADP-induced platelet aggregation
activities (Rabini et al., 1998; Gruzdeva et al., 2008; Tokuda et al.,
2012). The very elevated glycosylation of the platelet membrane
proteins, rather than molar ratio of cholesterol and phospho-
lipids, can decrease platelet membrane fluidity in diabetic patients
(Muratova, 2004; Vinik and Erbas, 2013). Increased glycosylation
of platelet proteins modulates cellular functions in diabetes. In
particular, possible glycosylation of calmodulin that modulates
activity of nitric oxide synthase (NOS) results in the decreased
synthesis of nitric oxide (NO) (Kutti et al., 1986).
The experimental studies demonstrated that C-peptide in vitro
modulates thrombogenesis (Lindenblatt et al., 2006). In our
study, we demonstrated positive association of the basal level
of C-peptide with the degrees and rates of the collagen- and
ADP-induced platelet aggregation (Suslova et al., 2007; Gruzdeva
et al., 2008). These positive correlations suggest interplay between
the elevated basal C-protein blood level and platelet aggrega-
tion in T2DM. Apparently, insulin resistance, hyperglycemia, and
elevated non-enzymatic protein glycosylation in T2DM are the
factors causing increased platelet sensitivity to the inductors of
platelet aggregation (Gruzdeva et al., 2008).
Some data suggest that hyperglycemia contributes to platelet
aggregation whereas normalization of glucose concentration
attenuates this process (Dandona and Aljada, 2004). The study
by P. Gresele et al. shows that single short-time elevation of the
glucose concentration triggers rapid increase in the platelet acti-
vation in T2DMpatients. This result is confirmed by the increased
interaction of platelets with collagen, elevated expression of
activation-associated platelet antigen, and augmented urinary
excretion of 1-dehydro-TxB2, the marker of platelet activation
(Gresele et al., 2010). High glucose concentrations hypothetically
activate endothelial NOS in platelets via the osmotic mechanisms
involving protein kinase C-β isoform and intracellular calcium
increase (Gkaliagkousi et al., 2007).
The molecule of NO is a universal regulator in the cardio-
vascular, immune, and nervous systems of the organism. NO is
synthesized both in endothelial, neural, smooth muscle cells, and
in platelets. This molecule thereby mediates autoregulation of
platelet activity. NO is a neutral radical with unpaired electron.
This molecule has the highest diffusion coefficient compared with
other molecules (O2 and CO2) in the organism and freely pene-
trates cellular membranes (Malakhov et al., 2009). The synthesis
of NO occurs via NO-synthase (NOS) that exists in three iso-
forms: neuronal (nNOS, NOS-1), inducible (iNOS, NOS-2), and
endothelial (eNOS, NOS-3) (Randriamboavonjy and Fleming,
2005). Enzymes catalyze the five-electron oxidation of L-arginine
to L-citrulline and NO. Both constitutive and inducible NOSs are
expressed in many cell types. Moreover, the isoforms of constitu-
tive NOSs are considered to be parts of two signaling pathways in
the cell (Malakhov et al., 2009). There are many publications that
reveal the involvement of iNOS in physiological synthesis of NO
and impact of eNOS and nNOS on extra synthesis of NO in infec-
tion, allergic, and autoimmune diseases (Wahl et al., 2003; Jarazo-
Dietrich et al., 2012; Singer et al., 2013). Activation of iNOS is a
component of many protective-adaptive reactions (Das and Das,
2008; Ye et al., 2010; Abu-Amara et al., 2012). The basal iNOS-
catalyzed NO production and its role in the regulation of vascular
tone remain under discussion (Granik et al., 1997; Bondarenko
et al., 2002). When eNOS is expressed in plasmamembrane of the
endotheliocytes (EC) and colocalized with caveolin, its activity is
very low. A variety of receptor-dependent stimuli (acetylcholine,
bradykinin, histamine, and thrombin) trigger the displacement
(extrusion) of eNOS from the complex of caveolin-eNOS and
elevate calcium concentration in EC leading to the release of
eNOS from caveolin-eNOS complex, its activation by calcium-
calmodulin, L-arginine oxidation, and synthesis of small (pico-
molar) quantities of NO (Oemar et al., 1998; Malakhov et al.,
2009). Free fatty acids that are often elevated in obesity inhibit
eNOS in vitro (Scherrer and Sartori, 1997). According to some
studies, platelet eNOS activity is lower in diabetic patients com-
pared with healthy individuals (Randriamboavonjy and Fleming,
2005). Available literature highlights the fact that platelet eNOS
can be activated by β2-adrenoceptors that activate adenylate
cyclase. Therefore, eNOS activation in platelets is possible due to
cAMP increase and protein kinase A (PKA) upregulation which
demonstrates close association between cAMP and cGMP systems
(Gkaliagkousi et al., 2007).
Activation of iNOS results in synthesis of high NO concentra-
tions enough to stimulate T-cell-mediated immunity and exert
cytotoxic effects. iNOS is identified in macrophages, neutrophils,
keratinocytes, fibroblasts, chondrocytes, osteoklasts, neurons,
astrocytes, various epithelial cells (respiratory, retinal, pigment,
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renal, tubular, and adenocarcinomatous), hepatocytes, pancreatic
β-cells, endotheliocytes, endocardiocytes, and vascular smooth
muscle cells. The enzyme is activated by cytokines or bacterial
antigens in inflammation as well as by ultraviolet, ozone, nico-
tinic acid, and hormones affecting cAMP synthesis (adrenalin,
glucagon). This NOS isoform generates manifold NO amount
compared with other forms of NOSs and does not require Ca2+
for this process (Malakhov et al., 2009). Our study demonstrated
an increased basal NO production by monocytes isolated from
MetS patients perhaps due to the iNOS activation (Suslova et al.,
2005).
NO stimulates synthesis of endothelial growth factor, but sup-
presses smooth muscle cells proliferation and migration thus
preventing neointima formation and vascular hypertrophy. Low
concentration of this molecule attenuate whereas high concen-
tration stimulate apoptosis and suppress extracellular matrix
synthesis thus maintaining normal structure of the vascular
wall (Malakhov et al., 2009). NO exerts anti-inflammatory and
antithrombogenic properties: (i) suppressing transcription of the
anti-inflammatory transcription factor, nuclear factor-kappa-B
(NF-kB) (Smolenski, 2012); (ii) inhibiting cytokine-stimulated
expression of the adhesive endothelial molecules [VCAM-1, E-
selectin, and monocyte chemoattractant protein (MCP)] and
monocyte chemotactic peptides (Berezova and Korovkin, 1998);
(iii) attenuating neutrophil and monocyte adhesion, infiltration,
and aggregation preventing conversion of the latter into the
macrophages; (iv) suppressing platelet aggregation and adhesion;
and (v) decreasing the expression of platelet-activating factor
and thrombus formation. Inhibition of NOS in healthy volun-
teers significantly increases blood clotting time and worsens other
coagulogram indices (Malakhov et al., 2009).
The ability of NO to directly interact with iron mediates
many physiological and toxic effects. NO reversibly binds to
heme iron of guanylate cyclase, cyclooxygenase, catalase, lipoxy-
genases, NOSs, cytochrome P450, peroxidases, and cytochromes
of mitochondrial respiratory electron transport chain as well as
to heme iron of oxyhemoglobin. Among these enzymes, guany-
late cyclase is of exceptional importance. Due to binding of NO
to Fe2+ of the guanylate cyclase porphyrin ring, the activity of
the enzyme increases by a factor of hundreds. As a result, syn-
thesized cyclic guanosine monophosphate regulates the vascular
tone, immune reactions, neuronal mediation, platelet aggrega-
tion, platelet-endothelial interactions, and functioning of the
diverse muscle cell types between other processes. Unlike guany-
late cyclase, inhibition of all other heme-containing enzymes does
not depend on heme iron valence in their active site when they
interact with NO (Malakhov et al., 2009).
Studies showed that NO enhance cGMP synthesis through the
activation of soluble guanylate cyclase (Randriamboavonjy and
Fleming, 2005; Gkaliagkousi et al., 2007). Further, cGMP can
downregulate cGMP-dependent Ca2+ channels or activate pro-
tein kinases G (cGMP-dependent protein kinases) (Bode-Böger
et al., 1998; Buvaltsev, 2011). In human platelets, there is evidence
of NO/cGMP-dependent inhibition of phospholipase C and, pos-
sibly, inositol trisphosphate receptor (InsP3R) phosphorylation
resulting in the receptor desensitization. Additionally, protein
kinases G upregulate protein phosphatase activating K+-channels
by dephosphorylation. All these processes eventually decrease the
cytoplasmic levels of free Ca2+ (Malakhov et al., 2009).
The activating effects of NO on cADP-ribosyltransferase
through the cGMP-dependent mechanisms were also demon-
strated. Synthesis of cADP-ribose, an agonist of ryanodine
receptors, augments Ca2+ release from endoplasmic reticulum.
Therefore, NO can both decrease and augment free Ca2+ concen-
tration in cytosol through the cGMP-dependent pathway (Granik
et al., 1997). One of the explanations of this phenomenon is
organospecificity, related, in particularly, to diverse development
of the endoplasmic reticulum and plasma membrane as well
as peculiarities of the intracellular metabolism in different cell
types. One can assume that the sophisticated andmultidirectional
effects of NO provide spatial and temporal regulatory tuning
of the cytosolic Ca2+ levels ultimate for proper cell functioning
(Malakhov et al., 2009).
There is evidence of decrease in the insulin-stimulated NO
production by the endothelial and smooth muscle cells in the
presence of insulin resistance (Bondarenko et al., 2002). In dia-
betes, platelet adhesion and spontaneous aggregation increase
as well. Altered activity of NOS in platelets from patients with
MetS can play the key role in onset of the platelet hyperac-
tivation and development of macro- and micro-angiopathies.
Studies of NO production in the platelets showed decreased
basal NO production in all groups of MetS patients compared
with healthy donors. Moreover, the lowest rates of NO syn-
thesis were observed in patients with decompensated T2DM
(Ogurkova et al., 2007). There is reverse correlation between
the NO-mediated synthesis of cGMP in platelets and the lev-
els of glucose and glycated hemoglobin in blood (Gkaliagkousi
et al., 2007; Naseem and Riba, 2008). Reduced basal formation
of NO by the cells from MetS patients can be caused by various
reasons. The presence of hyperglycemia due to glucose autoxida-
tion contributes to the formation of superoxide anion interacting
with NO and mediating formation of the peroxinitrite attenuat-
ing NO content (Schaeffer et al., 1999). There is evidence that
platelets express functional Ca2+-calmodulin-dependent consti-
tutive NOS. Glycosylation of calmodulin can cause reduction
of basal NO secretion. Additionally, the metabolic abnormalities
can affect NOS expression in megakaryocytes and downregulate
activity of the enzyme in platelets (Granik et al., 1997; Ogurkova
et al., 2007). The experimental and clinical studies suggest that
prolonged hyperglycemia contributes to the activation of the
polyol pathway of glucose metabolism with depletion of NADP
which is an obligatory cofactor of eNOS (Bondarenko et al.,
2002). In vitro and in vivo studies demonstrated that oxidized
low-density lipoproteins suppress platelet NO synthesis and stim-
ulate platelet aggregation and formation of thromboxane A2 and
serotonin (Malakhov et al., 2009).
Human platelet aggregation is also modulated by NO and
prostacyclin (PGI2) released from the endothelium. Endothelial
dysfunction, accompanying the insulin resistance syndrome,
attenuates NO and PGI2 production in the endotheliocytes
(Dandona and Aljada, 2004). Effects of NO and PGI2 on the
platelets are mediated by the adenylate and guanylate cycases
that synthesize cAMP and cGMP. The adenylate and guany-
late cyclases are regulated by prostacyclin and NO, respectively.
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Formed cGMP inhibits phosphodiesterases metabolizing cAMP
(Naseem and Riba, 2008; Stalker et al., 2012). Cyclic nucleotides
stimulate cAMP-dependent PKA and cGMP-dependent protein
kinase G (PKG) that, in turn, phosphorylate broad range of
proteins. Phosphorylation results in an inactivation of small
G proteins that belong to Ras and Rho families, inhibition of
Ca2+ release from the intracellular stores, and modulation of
actin cytoskeleton (Smolenski, 2012). Degradation of cAMP and
cGMP is mediated by phosphodiesterases (Smolenski, 2012).
Abnormalities in cAMP/cGMP pathways can cause platelet hyper-
activity (Dandona and Aljada, 2004; Inada et al., 2008; Stalker
et al., 2012; Shaturny et al., 2014). For example, De La Cruz
et al. observed a decrease in cGMP content in patients with dia-
betic retinopathy and decrease in activity of platelet adenylate
cyclase (De La Cruz et al., 2002). According to literature, platelets
from patients with diabetes have decreased sensitivity to NO and
PGI2. In diabetes mellitus, the number of PGI2 receptors is not
decreased suggesting that the defect is downstream of the recep-
tor. Livingstone et al. detected a decrease in Gi protein in the
platelet membranes from T2DM patients. Some studies demon-
strated elevated activity of cGMP-dependent phosphodiesterase
eventually leading to decrease in sensitivity to NO (Vinik and
Erbas, 2013). State-of-the-art proteomic approaches with the use
of antibodies against eNOS suggest the presence of 135-kDa pro-
tein in human platelets though data are inconclusive on whether
the protein is eNOS (Naseem and Riba, 2008). Inhibitors of NOS
do not affect human platelet activation at all and there are no dif-
ferences between the agonist-induced platelet aggregation in wild
type and NOS-deficient mice. It is important to note that iNOS
and eNOS mRNAs are found in human platelets by the standard
methods (Gkaliagkousi et al., 2007) though the use of new tech-
nologies does not confirm this fact. The hypothesis, based on
this fact, states that some platelet agonists directly affect solu-
ble guanylate cyclases triggering NO-independent activation of
cGMP-dependent signaling pathway (Naseem and Riba, 2008).
Though NOS regulation in platelets is currently under discussion,
the insulin-induced cGMP synthesis is decreased and agonist-
induced platelet aggregation is insensitive to NOS inhibitors in
T2DM patients (Randriamboavonjy and Fleming, 2009).
In our study, N-monomethyl-L-arginine (L-NMMA), a
blocker of eNOS and iNOS, was used for evaluation of the
involvement of NOS into antiplatelet effects of insulin. Both in
healthy volunteers and patients with MetS, the collagen-induced
platelet aggregation did not change in response to insulin. These
data agree with the hypothesis suggesting absence of NOS in
platelets (Kawamato et al., 2002). Similarly to its macrophage
form, iNOS was found on the mitochondrial inner membrane
(Joannides et al., 1995). Platelets contain significant amount
of mitochondria and, therefore, iNOS can be present in these
organelles. So what is the reason that the enzyme is difficult to
detect in platelets? As known, platelet lifetime is not long and
lasts for no more than 7–10 days. Half-life time of NOS is quite
short (15–20 h); the enzyme is subject to the phosphorylation on
tyrosine, serine, or threonine residue and can be easily oxidized
by nitric monoxide produced by NOS itself or by other oxi-
dants (anion-radical, hydrogen peroxide) (Malakhov et al., 2009).
De novo protein synthesis in platelets is significantly limited due
to the absence of nucleus. It is possible, that NOSs are present in
younger platelets, but, due to rapid degradation of the enzymes
and small lifetime of the platelets, NOSs are impossible to detect.
Hyperhomocysteinemia is often associated with T2DM and
represents a risk factor for cardiovascular catastrophes (Boushey
et al., 1995). Homocysteine affects blood vessels through the
active oxygen forms, decrease in endothelial NO production, and
augmentation of smooth muscle cell proliferation (Welch and
Loscalzo, 1998). The study of B. Mutus et al. showed an asso-
ciation of in vivo and in vitro decreases in the NO production
with the elevated homocysteine levels in healthy volunteers and
diabetic patients (Mutus et al., 2001). At the same time, NO pro-
duction after incubation with homocysteine is lower in cells from
diabetic patients than in healthy individuals. Homocysteine can
decrease platelet NO production by several mechanisms: (i) direct
binding with formation of S-nitrohomocysteine; (ii) formation
of superoxide anion and hydrogen peroxide followed by decrease
in bioavailability of NO (Paolocci et al., 2001); and (iii) activa-
tion of iNOS accompanied by the synthesis of superoxide anion
and NO whose interaction results in formation of peroxinitrate
(Schaeffer et al., 1999; De La Cruz et al., 2002). Data demon-
strated that homocysteine causes atherogenic effects in diabetic
patients due to decreased platelet NO production with following
augmentation of platelet activity and aggregation (Mutus et al.,
2001).
Human platelets express insulin receptors on the cell surface,
suggesting possible involvement of insulin in the platelet reg-
ulation. According to existing experimental evidence of insulin
effects on platelet aggregation, in case of incubation with physi-
ologic concentrations of insulin for 3–20min, platelets respond
with decreased aggregation induced by the following agonists:
ADP, adrenalin, and collagen. Insulin also decreases thrombin-
and angiotensin II-induced platelet aggregation (Udvardy et al.,
1985; Trovati et al., 1998; Shitikova, 2000). Data show that
anti-aggregation effects of insulin can be mediated through dif-
ferent intracellular mechanisms. In smooth muscle cells, insulin
increases cGMP and cAMP contents by NO-dependent mecha-
nism activating NOS and transport of L-arginine into the cells
(Scherrer and Sartori, 1997; Westerbacka et al., 2002). The effects
of insulin on platelets in healthy individuals consist in the
NO-mediated elevation of cGMP and cAMP, decrease in Ca2+
currents induced by Ca2+ mobilizing agents, decrease in agonist-
induced aggregation, augmentation of platelet binding with anti-
aggregation prostanoids, and suppression of platelet binding with
catecholamines leading to adrenalin-induced platelet aggregation
(Udvardy et al., 1985; Shitikova, 2000; Suslova et al., 2007). In
insulin resistant patients, calcium content in platelets rises in
response to stimulation by insulin, leading thereby to platelet acti-
vation and aggregation (Schaeffer et al., 1999; Westerbacka et al.,
2002; Paneni et al., 2013).
Decrease in the number and sensitivity of insulin receptors on
platelets in T2DM patients can result in platelet hyperactivation
(Udvardy et al., 1985). On the other hand, a decrease in platelet
sensitivity to insulin can be caused by abnormal intracellular
insulin signaling by second messenger system (Bode-Böger et al.,
1998; Trovati et al., 1998; Dandona and Aljada, 2004; Ogurkova
et al., 2012). The study of individuals with abnormal carbohydrate
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metabolism demonstrated augmentation of platelet activity and
aggregation in response to an increase in content of cGMP exert-
ing anti-aggregation effect. The authors assume that elevated
platelet aggregation in these patients causes cGMP increase by the
negative feedback mechanism (Anwaar et al., 2000). Westerbacka
J. et al. studied the regulation of platelets in individuals with
and without obesity. They showed that the in vivo infusion of
insulin suppresses platelet adhesion on collagen in individuals
with normal weight, but not in obese patients. Moreover, only
in the absence of obesity, insulin significantly elevates cGMP
concentration in platelets contributing to platelet inactivation
following the adhesion. These data suggest the hypothesis of
insulin-mediated suppression of the interaction between platelets
and collagen in normal conditions. In obesity, this effect of insulin
is absent suggesting the existence of additional mechanism of
pathogenic interplay between insulin resistance and atherothrom-
bosis (Anfossi et al., 1998; Westerbacka et al., 2002). According to
our data on healthy volunteers and patients with MetS and heart
failure (Ogurkova et al., 2012), platelets, incubated with the phys-
iological concentrations of insulin (1 nM) for 3min, respond with
decrease in a degree and rate of collagen-induced platelet aggrega-
tion, determined based on the curves of the mean aggregate size
and light transmission. Also, literature presents reports describ-
ing a decrease in platelet aggregation induced by other activators
(ADP, thrombin, arachidonate, and platelet-activating factor) in
the presence of insulin (Vinik and Erbas, 2013).
In our study, isolated platelets were incubated with insulin
and treated with blockers of cGMP- and cAMP-dependent phos-
phodiesterases. Phosphodiesterases inhibitors increased intra-
cellular concentrations of cyclic nucleotides and significantly
decreased collagen-induced platelet aggregation both in MetS
patients and healthy volunteers (Ogurkova et al., 2012). A
scheme illustrating the interactions of the signaling pathways and
effects of the modulators is presented in Figure 1. More pro-
nounced decrease in collagen-induced aggregation of platelets,
incubated in the media containing mix of insulin and phos-
phodiesterase inhibitors, suggests a synergy of the inductors
(Ogurkova et al., 2012). The overlapping observations on the
insulin-induced platelet aggregation and cGMP contents in
healthy individuals and patients with insulin resistance con-
firm that cGMP increase in platelets is the main mechanism of
insulin-induced modulation of platelet function. M. Trovati et al.
demonstrated similar effects of various insulin concentrations
on platelet aggregation and cGMP contents in different sub-
jects, namely: supraphysiological concentrations (1920 pmol/L)
in obese or diabetic patients with obesity and more physio-
logical concentrations (240–480 pmol/L) in healthy individuals
(Trovati et al., 1995).
Some authors consider platelets as the source of active synthe-
sis of humoral factors simultaneously stimulating the processes
of thrombus formation and inflammation (Soslau et al., 1997).
Recently, platelet ability to release anti-inflammatory cytokine
interleukin-1 (IL-1) and other inflammatory mediators was dis-
covered. Platelets also express adhesive molecules, chemokines,
and growth factors (Anfossi et al., 2010; Beaulieu et al., 2014).
According to the study by Lea M. Beaulieu et al. IL-1β augments
agonist-induced platelet aggregation by 1.2 times in response to
collagen and by 4.2 times in response to thrombin. However,
different concentrations of IL-1β do not affect aggregation of
the isolated platelets. These data lay the foundation for the
hypothesis that IL-1β modulates effects of aggregation agonists
by influencing the signaling cascades (Beaulieu et al., 2014).
Interleukin-6 (IL-6) can stimulate thrombocytopoesis; in the
presence of IL-6, nascent platelets have an increased sensitiv-
ity to thrombin and procoagulant activity (Esmon, 1999, 2004;
Anfossi et al., 2010). It is known that proinflammatory cytokines
participate in the development of dyslipidemia and insulin resis-
tance and are the markers of T2DM and its complications.
Studies of anti-inflammatory cytokine tumor necrosis factor α
(TNF-α) demonstrated its relationships with obesity and insulin
resistance. Adipose tissue produces large amounts of TNF-α
whereas knockout mice deficient on TNF-α or its receptor are
protected from developing the insulin resistance (Nieto-Vazquez
et al., 2008; Anfossi et al., 2010). According to various stud-
ies, this adipocytokine stimulates biosynthesis of plasminogen
activator inhibitor-1 (PAI-1) in different cell cultures and in
many mouse tissues in vivo as well as blocks insulin effects by
decreasing activity of insulin receptor tyrosine kinase. The rela-
tionships between MetS and fibrinolysis deficiency, caused by
the elevated level of PAI-1, are currently known. Plasminogen
activator inhibitor-1 is the main physiologic plasminogen acti-
vator inhibitor in vivo suppressing fibrin and contributing to
fibrin fibers dissolving (Esmon, 2004; Petrik and Pavlishchuk,
2008; Paneni et al., 2013). The studies in vitro showed that
TNF-α stimulates platelet aggregation and production of active
oxygen forms mostly through the activation of arachidonic acid
metabolism (Pignatelli et al., 2005; Pircher et al., 2012). On
the other hand, according to data of Cambien B. et al. gen-
erated in the experiments of mice, tumor necrosis factor in
high concentrations (1 ng/mL) exerts the anti-thrombotic action,
decreases platelet aggregation activity, and inhibits thrombus
formation. The authors assume that anti-thrombotic action of
TNF-α is mediated indirectly through the rapid NO release by
the endothelial cells of the vascular wall rather than through
the interaction with platelets (Cambien et al., 2003). Busse and
Mülsch demonstrated the evidence of cytokine (TNF-α, IL-1)-
induced expression of eNOS in aortic endothelial cells (Busse and
Mülsch, 1990). We studied the effects of TNF-α and IL-1β on
the aggregation activity of isolated platelets from patients with
MetS and healthy volunteers. According to our data (Periodic
Report 2 - SICA-HF1 ), incubation of isolated platelets with
TNF-α in concentrations of 0.05 and 1 ng/mL in the reaction
media decreases collagen-induced cell aggregation in group of
patients with metabolic abnormalities and in healthy volun-
teers, though this response is significantly more pronounced
in MetS patients. Additional application of NOS inhibitor, L-
NMMA, in the incubation medium affected collagen-induced
platelet aggregation in the presence of TNF-α and IL-1β nei-
ther in group of patients with MetS nor in control group.
According to our data (Periodic Report 2 - SICA-HF), TNF-α
1Periodic Report 2 - SICA-HF (Studies investigating co-morbidities aggra-
vating heart failure). Record Number: 94060. Last updated on: 2013-11-28.
Available at http://cordis.europa.eu/publication/rcn/14456_en.html.
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FIGURE 1 | Signaling pathway interaction and effects of modulators: cGMP and cAMP-dependent intracellular signaling systems in the insulin-mediated
regulation of platelet aggregation in patients with metabolic disorders.
and IL-1β exert NO-independent anti-aggregation effects on iso-
lated human platelets independently on the presence of insulin
resistance in the subjects.
Gareth J. Padfield et al. studied the effects of intravenous
infusion of etanercept (TNF-α receptor antagonist) in patients
with acute myocardial infarction. Infusion of etanercept in a
dose of 10mg decreased the neutrophil count and IL-6 level,
but enhanced the platelet-monocytic aggregation (Padfield et al.,
2013). Joachim Pircher et al. studied the effects of TNF-α
(5 ng/mL) on hemostasis inmice and concluded that this cytokine
exerts prothrombotic action. The authors explained prothrom-
botic action of TNF-α by endothelial activation. However, their
results were still inconclusive in regard whether the effects
on the platelets were direct (Pircher et al., 2012). Pasquale
Pignatelli et al. studied platelet activation in patients with heart
failure in response to stimulation by tumor necrosis factor.
Researchers found that physiologic concentrations of TNF-α (20–
40 pg/mL) do not affect platelet aggregation (Pignatelli et al.,
2005). Therefore, the currently available data cannot unambigu-
ously resolve the question whether the effects of TNF-α are pro-
thrombotic or antithrombotic (Anfossi et al., 2010). This question
remains to be explored.
CONCLUSION
Platelet activation causes high risk of cardiovascular complica-
tions in MetS. T2DM is associated with the changes in the intra-
cellular signaling systems regulating platelet functions. Due to the
altered NOS expression and activity, platelets increase their pro-
thrombogenic potential. The cGMP-mediated antiaggregational
effects of insulin, involving NOS and NO-dependent mecha-
nisms, become abnormal. The effects of aggregation-triggering
agonists are modulated by the proinflammatory factors. All these
mechanisms of changes in platelets aggregation activity in MetS
and DMT2 are caused by the metabolic disturbances including
insulin resistance, hyperglycemia, and dyslipidemia. Future stud-
ies of the second messenger systems involved in the platelet
aggregation/anti-aggregation mechanisms are required. Further
investigations should be focused on an identification of the
abnormalities in these systems at early stages of metabolic dis-
orders in patients. Results of such studies may lay a foundation
for a discovery of new approaches for prevention and treatment
of cardiovascular complications in MetS and DMT2.
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